Efficacy of multiple anticancer therapies may depend on host immune response

Kritika Karri, Dhundy R. Bastola

Research output: Contribution to journalArticle

Abstract

The host immune system is a key player in anticancer therapy response and resistance. Although the impact of host immune response in the 'war against cancer' has been studied and it has been the basis for immunotherapy, understanding of its role in attenuating the action of conventional anticancer therapies is an area that has not been fully explored. In spite of advances in systemic therapy, the 5-year survival rate for adenocarcinoma is still a mere 13% and the primary reason for treatment failure is believed to be due to acquired resistance to therapy. Hence, there is a need for identifying reliable biomarkers for guided treatment of lung and colon adenocarcinoma and to better predict the outcomes of specific anticancer therapies. In this work, gene expression data were analyzed using public resources and this study shows how host immune competence underscores the efficacy of various anticancer therapies. Additionally, the result provides insight on the regulation of certain biochemical pathways relating to the immune system, and suggests that smart chemotherapeutic intervention strategies could be based on a patient's immune profile.

Original languageEnglish (US)
Pages (from-to)773-788
Number of pages16
JournalAdvances in Science, Technology and Engineering Systems
Volume2
Issue number3
DOIs
StatePublished - Jan 1 2017

Fingerprint

Immune system
therapy
Biomarkers
Gene expression
immune systems
biomarkers
gene expression
lungs
Efficacy
Therapy
resources
cancer
profiles

Keywords

  • Alkylating agents
  • Anti-angiogenesis
  • Antimetabolite
  • Biomarker
  • Colon adenocarcinoma
  • Complete Remission
  • GSEA
  • Immune response
  • Lung adenocarcinoma
  • Mitotic inhibitors
  • Progressive Disease

ASJC Scopus subject areas

  • Engineering (miscellaneous)
  • Physics and Astronomy (miscellaneous)
  • Management of Technology and Innovation

Cite this

Efficacy of multiple anticancer therapies may depend on host immune response. / Karri, Kritika; Bastola, Dhundy R.

In: Advances in Science, Technology and Engineering Systems, Vol. 2, No. 3, 01.01.2017, p. 773-788.

Research output: Contribution to journalArticle

@article{28c5ac2e9a634396b3d605d900872c44,
title = "Efficacy of multiple anticancer therapies may depend on host immune response",
abstract = "The host immune system is a key player in anticancer therapy response and resistance. Although the impact of host immune response in the 'war against cancer' has been studied and it has been the basis for immunotherapy, understanding of its role in attenuating the action of conventional anticancer therapies is an area that has not been fully explored. In spite of advances in systemic therapy, the 5-year survival rate for adenocarcinoma is still a mere 13{\%} and the primary reason for treatment failure is believed to be due to acquired resistance to therapy. Hence, there is a need for identifying reliable biomarkers for guided treatment of lung and colon adenocarcinoma and to better predict the outcomes of specific anticancer therapies. In this work, gene expression data were analyzed using public resources and this study shows how host immune competence underscores the efficacy of various anticancer therapies. Additionally, the result provides insight on the regulation of certain biochemical pathways relating to the immune system, and suggests that smart chemotherapeutic intervention strategies could be based on a patient's immune profile.",
keywords = "Alkylating agents, Anti-angiogenesis, Antimetabolite, Biomarker, Colon adenocarcinoma, Complete Remission, GSEA, Immune response, Lung adenocarcinoma, Mitotic inhibitors, Progressive Disease",
author = "Kritika Karri and Bastola, {Dhundy R.}",
year = "2017",
month = "1",
day = "1",
doi = "10.25046/aj020398",
language = "English (US)",
volume = "2",
pages = "773--788",
journal = "Advances in Science, Technology and Engineering Systems",
issn = "2415-6698",
publisher = "ASTES Publishers",
number = "3",

}

TY - JOUR

T1 - Efficacy of multiple anticancer therapies may depend on host immune response

AU - Karri, Kritika

AU - Bastola, Dhundy R.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The host immune system is a key player in anticancer therapy response and resistance. Although the impact of host immune response in the 'war against cancer' has been studied and it has been the basis for immunotherapy, understanding of its role in attenuating the action of conventional anticancer therapies is an area that has not been fully explored. In spite of advances in systemic therapy, the 5-year survival rate for adenocarcinoma is still a mere 13% and the primary reason for treatment failure is believed to be due to acquired resistance to therapy. Hence, there is a need for identifying reliable biomarkers for guided treatment of lung and colon adenocarcinoma and to better predict the outcomes of specific anticancer therapies. In this work, gene expression data were analyzed using public resources and this study shows how host immune competence underscores the efficacy of various anticancer therapies. Additionally, the result provides insight on the regulation of certain biochemical pathways relating to the immune system, and suggests that smart chemotherapeutic intervention strategies could be based on a patient's immune profile.

AB - The host immune system is a key player in anticancer therapy response and resistance. Although the impact of host immune response in the 'war against cancer' has been studied and it has been the basis for immunotherapy, understanding of its role in attenuating the action of conventional anticancer therapies is an area that has not been fully explored. In spite of advances in systemic therapy, the 5-year survival rate for adenocarcinoma is still a mere 13% and the primary reason for treatment failure is believed to be due to acquired resistance to therapy. Hence, there is a need for identifying reliable biomarkers for guided treatment of lung and colon adenocarcinoma and to better predict the outcomes of specific anticancer therapies. In this work, gene expression data were analyzed using public resources and this study shows how host immune competence underscores the efficacy of various anticancer therapies. Additionally, the result provides insight on the regulation of certain biochemical pathways relating to the immune system, and suggests that smart chemotherapeutic intervention strategies could be based on a patient's immune profile.

KW - Alkylating agents

KW - Anti-angiogenesis

KW - Antimetabolite

KW - Biomarker

KW - Colon adenocarcinoma

KW - Complete Remission

KW - GSEA

KW - Immune response

KW - Lung adenocarcinoma

KW - Mitotic inhibitors

KW - Progressive Disease

UR - http://www.scopus.com/inward/record.url?scp=85069462411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069462411&partnerID=8YFLogxK

U2 - 10.25046/aj020398

DO - 10.25046/aj020398

M3 - Article

AN - SCOPUS:85069462411

VL - 2

SP - 773

EP - 788

JO - Advances in Science, Technology and Engineering Systems

JF - Advances in Science, Technology and Engineering Systems

SN - 2415-6698

IS - 3

ER -